50461-51-3

Basic information

• Product Name: 1',2',3',6'-TETRAHYDRO-[2,4']BIPYRIDINYL
• Synonyms: 1',2',3',6'-TETRAHYDRO-[2,4']BIPYRIDINYL
• CAS NO: 50461-51-3
• Molecular Formula: C₁₀H₁₂N₂
• Molecular Weight: 160.21568
• Mol File: 50461-51-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1',2',3',6'-TETRAHYDRO-[2,4']BIPYRIDINYL(CAS DataBase Reference)
• NIST Chemistry Reference: 1',2',3',6'-TETRAHYDRO-[2,4']BIPYRIDINYL(50461-51-3)
• EPA Substance Registry System: 1',2',3',6'-TETRAHYDRO-[2,4']BIPYRIDINYL(50461-51-3)

Safety Data

• Hazardous Substances Data: 50461-51-3(Hazardous Substances Data)

Usage

Chemical structure

Tetrahydrobipyridine compound

Pharmacological activity

Potential as a therapeutic agent for various conditions

Central nervous system

Acts as a depressant

Potential therapeutic applications

Addiction, anxiety, and pain management

Mechanism of action

Interacts with the brain's GABA receptors

Effects

Sedative and anxiolytic (anxiety-reducing) properties

Neurological disorders

Studied for potential treatment of Parkinson's disease and epilepsy

Ongoing research

Continued investigation into its therapeutic applications and potential benefits
These properties and contents are based on the information provided and highlight the compound's potential uses and areas of study.

Upstream product

• 90606-75-0 4'-Hydroxy-3',4',5',6'-tetrahydro-2'H-[2,4']bipyridinyl-1'-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 41979-39-9 4-piperidone hydrochloride 
• 109-04-6 2-bromo-pyridine 
• 90606-77-2 3',6'-dihydro-2'H-[2,4']bipyridinyl-1'-carboxylic acid tert-butyl ester 

Downstream Products

• 1197901-70-4 (2R,3R)-2-(2,4-difluorophenyl)-3-(3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol 
• 30532-37-7 4-(2-pyridinyl)piperidine 
• 182415-09-4 Piclozotan 

Relevant articles and documents

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

Aryl-tetrahydropyridine derivatives were prepared and their PPARα/γ dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPARα/γ dual agonist with an EC50 of 1.73 and 0.64 μM in hPPARα and γ, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties.